Answers are grounded in this paper and cite their sources.
To the Editor: Epstein et al1Epstein DJ, Tan SK, Deresinski S. HHV-6 and septic shock: tenuous proof of causation [published online ahead of print 2018]. Am J Transplant. https://doi.org/10.1111/ajt.14983.Google Scholar point out that proof of a causal relationship between human herpesvirus (HHV)-6 reactivation and septic shock is tenuous in Bonnafous et al2Bonnafous P Marlet J Bouvet D et al.Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation.Am J Transplant. 2018; 18: 1548-1551Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar and state that “no high-quality data support the use of antivirals for HHV-6-associated syndromes.” HHV-6 can cause significant disease in hematopoietic stem cell transplant (HCT) and solid organ transplant (SOT) patients, which has been successfully treated with foscarnet, ganciclovir, or, less commonly, cidofovir,3Ogata M Oshima K Ikebe T et al.Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2017; 52: 1563-1570Crossref PubMed Scopus (55) Google Scholar, 4Phan TL Lautenschlager I Razonable RR Munoz FM HHV-6 in liver transplantation: a literature review.Liver Int. 2018; 38: 210-223Crossref Scopus (26) Google Scholar, 5Buyse S Roque-Afonso A-M Vaghefi P et al.Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients.Am J Clin Pathol. 2013; 140: 403-409Crossref PubMed Scopus (22) Google Scholar, 6Politikos I McMasters M Bryke C Avigan D Boussiotis VA Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.Blood Adv. 2018; 2: 1367-1370Crossref PubMed Scopus (9) Google Scholar, 7Ogata M Takano K Moriuchi Y et al.Effects of prophylactic foscarnet on human herpesvirus-6 reactivation and encephalitis in cord blood transplant recipients: a prospective multicenter trial with an historical control group.Biol Blood Marrow Transplant. 2018; 24: 1264-1273Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar and we recently showed that foscarnet prophylaxis (90 mg/kg/day) may be able to reduce the severity of HHV-6 encephalitis,7Ogata M Takano K Moriuchi Y et al.Effects of prophylactic foscarnet on human herpesvirus-6 reactivation and encephalitis in cord blood transplant recipients: a prospective multicenter trial with an historical control group.Biol Blood Marrow Transplant. 2018; 24: 1264-1273Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar which affects 5.0% to 8.3% of cord blood transplant (CBT) patients and 0.5% to 2.3% of non-CBT alloHCT patients.3Ogata M Oshima K Ikebe T et al.Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2017; 52: 1563-1570Crossref PubMed Scopus (55) Google Scholar,8Scheurer ME Pritchett JC Amirian ES Zemke NR Lusso P Ljungman P HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis.Bone Marrow Transplant. 2013; 48: 574-580Crossref PubMed Scopus (88) Google Scholar Although HHV-6 disease is less common in liver transplant compared with HCT, it is underappreciated as infection can persist in the liver without evidence in peripheral blood.4Phan TL Lautenschlager I Razonable RR Munoz FM HHV-6 in liver transplantation: a literature review.Liver Int. 2018; 38: 210-223Crossref Scopus (26) Google Scholar,5Buyse S Roque-Afonso A-M Vaghefi P et al.Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients.Am J Clin Pathol. 2013; 140: 403-409Crossref PubMed Scopus (22) Google Scholar Epstein et al correctly pointed out that not all cases of HHV-6 infection need to be treated and cited Hill et al,9Hill JA Boeckh MJ Sedlak RH Jerome KR Zerr DM Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation.J Clin Virol. 2014; 61: 289-292Crossref PubMed Scopus (0) Google Scholar who demonstrated that 27% of HCT patients who had detectable levels of HHV-6 DNA in cerebrospinal fluid (CSF) had spontaneous resolution of symptoms, were asymptomatic, or had alternative diagnoses besides HHV-6 encephalitis. While this finding suggests that the detection of HHV-6 DNA in CSF, especially at low levels, does not unequivocally prompt a diagnosis of HHV-6 encephalitis, it does not rule out HHV-6 as an etiological agent for posttransplant morbidities.1Epstein DJ, Tan SK, Deresinski S. HHV-6 and septic shock: tenuous proof of causation [published online ahead of print 2018]. Am J Transplant. https://doi.org/10.1111/ajt.14983.Google Scholar In fact, a vast majority of these patients (73%) still had symptoms of HHV-6–associated central nervous system (CNS) dysfunction, all of whom were treated with ganciclovir and/or foscarnet.9Hill JA Boeckh MJ Sedlak RH Jerome KR Zerr DM Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation.J Clin Virol. 2014; 61: 289-292Crossref PubMed Scopus (0) Google Scholar Moreover, 16 of 17 CBT patients with detectable HHV-6 DNA in CSF developed HHV-6 CNS dysfunction,9Hill JA Boeckh MJ Sedlak RH Jerome KR Zerr DM Human herpesvirus 6 can be detected in cerebrospinal fluid without associated symptoms after allogeneic hematopoietic cell transplantation.J Clin Virol. 2014; 61: 289-292Crossref PubMed Scopus (0) Google Scholar underscoring the increased risk of HHV-6 encephalitis in CBT recipients.8Scheurer ME Pritchett JC Amirian ES Zemke NR Lusso P Ljungman P HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis.Bone Marrow Transplant. 2013; 48: 574-580Crossref PubMed Scopus (88) Google Scholar Epstein et al also asserted that HHV-6 antiviral prophylaxis has not demonstrated clinical effectiveness, citing our recent study.7Ogata M Takano K Moriuchi Y et al.Effects of prophylactic foscarnet on human herpesvirus-6 reactivation and encephalitis in cord blood transplant recipients: a prospective multicenter trial with an historical control group.Biol Blood Marrow Transplant. 2018; 24: 1264-1273Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar We agree with this point; thus, we concluded that the prophylactic foscarnet dose (90 mg/kg/day) was not high enough to sufficiently reduce the incidence of HHV-6 encephalitis8Scheurer ME Pritchett JC Amirian ES Zemke NR Lusso P Ljungman P HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis.Bone Marrow Transplant. 2013; 48: 574-580Crossref PubMed Scopus (88) Google Scholar or acute graft-versus-host disease10Phan TL, Carlin K, Ljungman P, et al. Human herpesvirus-6B reactivation is a risk factor for grades II to IV acute graft-versus-host disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis [published online ahead of print 2018]. Biol Blood Marrow Transplant. https://doi.org/10.1016/j.bbmt.2018.04.021.Google Scholar in CBT patients, especially under inflammatory conditions such as preengraftment immune reaction or steroid treatments, which are associated with a heavy HHV-6 burden. As such, the Japan Society for Hematopoietic Cell Transplantation has recommended a higher dose of foscarnet (180 mg/kg/day or 60 mg/kg intravenous every 8 hours) for the treatment of HHV-6 encephalitis. Given that the patient in Bonnafous et al weighed 93 kg and was treated with 6 g foscarnet/day (~65 mg/kg/day),2Bonnafous P Marlet J Bouvet D et al.Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation.Am J Transplant. 2018; 18: 1548-1551Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar this dose may have been inadequate to achieve clinical improvement. Around 3% of liver transplants can be complicated by inherited chromosomally integrated HHV-6 (iciHHV-6) because 2% of liver transplant recipients and 0.85% of control patients are affected by iciHHV-6.4Phan TL Lautenschlager I Razonable RR Munoz FM HHV-6 in liver transplantation: a literature review.Liver Int. 2018; 38: 210-223Crossref Scopus (26) Google Scholar Initial screening can be done with a single pretransplant qPCR test using whole blood.11Das BB Munoz FM Screening for chromosomally integrated human herpesvirus 6 status in solid-organ donors and recipients.J Heart Lung Transplant. 2017; 36: 481Abstract Full Text Full Text PDF Scopus (0) Google Scholar Failure to detect iciHHV-6 may result in unnecessary treatment with toxic antiviral agents; on the other hand, as Bonnafous et al demonstrated, iciHHV-6 reactivation can result in severe consequences for SOT patients.2Bonnafous P Marlet J Bouvet D et al.Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation.Am J Transplant. 2018; 18: 1548-1551Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar Ultimately, physicians should be aware that a recipient of an iciHHV-6+ organ may be vulnerable to HHV-6 reactivation and that certain drugs such as steroids and histone deacetylase inhibitors can promote the reactivation of iciHHV-6.4Phan TL Lautenschlager I Razonable RR Munoz FM HHV-6 in liver transplantation: a literature review.Liver Int. 2018; 38: 210-223Crossref Scopus (26) Google Scholar,6Politikos I McMasters M Bryke C Avigan D Boussiotis VA Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.Blood Adv. 2018; 2: 1367-1370Crossref PubMed Scopus (9) Google Scholar,11Das BB Munoz FM Screening for chromosomally integrated human herpesvirus 6 status in solid-organ donors and recipients.J Heart Lung Transplant. 2017; 36: 481Abstract Full Text Full Text PDF Scopus (0) Google Scholar The iciHHV-6 status of the recipient/donor must be considered before making treatment decisions regarding HHV-6 infections, particularly in the context of extremely high viral loads.11Das BB Munoz FM Screening for chromosomally integrated human herpesvirus 6 status in solid-organ donors and recipients.J Heart Lung Transplant. 2017; 36: 481Abstract Full Text Full Text PDF Scopus (0) Google Scholar Further study is required to elucidate the mechanisms by which HHV-6 causes disease.10Phan TL, Carlin K, Ljungman P, et al. Human herpesvirus-6B reactivation is a risk factor for grades II to IV acute graft-versus-host disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis [published online ahead of print 2018]. Biol Blood Marrow Transplant. https://doi.org/10.1016/j.bbmt.2018.04.021.Google Scholar,12Phan T, Zerr DM, Boussiotis V, Lusso P, Di Luca D. Considerations on human herpesvirus 6 reactivation after cord blood transplantation [published online ahead of print 2018]. Am J Hematol. https://doi.org/10.1002/ajh.25207.Google Scholar Because HHV-6 can establish localized infections in target organs4Phan TL Lautenschlager I Razonable RR Munoz FM HHV-6 in liver transplantation: a literature review.Liver Int. 2018; 38: 210-223Crossref Scopus (26) Google Scholar,5Buyse S Roque-Afonso A-M Vaghefi P et al.Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients.Am J Clin Pathol. 2013; 140: 403-409Crossref PubMed Scopus (22) Google Scholar (eg, lung, liver, and heart) with little footprint in the blood, biopsy studies are also warranted. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
No takes yet. Share an insight, caveat, or question.
Ogata et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: